Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction

IF 2.8 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Yuan Zhang, Ming Zhao, Lei Hou, Long Jin, Jun Bai, Yunzhi Dang
{"title":"Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction","authors":"Yuan Zhang,&nbsp;Ming Zhao,&nbsp;Lei Hou,&nbsp;Long Jin,&nbsp;Jun Bai,&nbsp;Yunzhi Dang","doi":"10.1111/cts.70368","DOIUrl":null,"url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with limited targeted therapeutic options. Exosomes, small membrane vesicles secreted by cells, play a crucial role in intercellular communication and material exchange. However, the role of exosome-related genes (ERGs) in TNBC remains unclear. In here, we analyzed single-cell RNA sequencing (scRNA-seq) from 10 TNBC samples and bulk RNA-seq from TCGA and METABRIC cohorts. Starting with 121 EDPS curated from the breast cancer-specific ExoBCD database, we identified exosome-active cell populations and derived an Exosome-Derived Prognostic Signature (EDPS) through integrative machine learning. Our analysis identified 31,140 cells from TNBC samples, categorized into nine cell types, with epithelial cells exhibiting the highest exosome-related scores. A total of 232 differentially expressed genes (DEGs) related to exosome-related scores were identified, with 19 prognostic genes selected through univariate Cox regression, leading to the construction of an EDPS. Low EDPS scores correlated with poorer clinical outcomes, higher immune infiltrates, and immune-related pathways. Furthermore, we identified notable differences in biological functions and mutation profiles between the two EDPS groups. Additionally, the low EDPS score group exhibited lower tumor immune dysfunction and exclusion (TIDE) scores, immunophenoscore (IPS), and higher immune checkpoint expression, suggesting better immunotherapy outcomes. In conclusion, while derived from exosome-related genes, the EDPS primarily reflects immune-active tumor microenvironments. This signature may help identify TNBC patients likely to benefit from immunotherapy, though further validation of its relationship to exosome biology is needed.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 10","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70368","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cts-Clinical and Translational Science","FirstCategoryId":"3","ListUrlMain":"https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70368","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with limited targeted therapeutic options. Exosomes, small membrane vesicles secreted by cells, play a crucial role in intercellular communication and material exchange. However, the role of exosome-related genes (ERGs) in TNBC remains unclear. In here, we analyzed single-cell RNA sequencing (scRNA-seq) from 10 TNBC samples and bulk RNA-seq from TCGA and METABRIC cohorts. Starting with 121 EDPS curated from the breast cancer-specific ExoBCD database, we identified exosome-active cell populations and derived an Exosome-Derived Prognostic Signature (EDPS) through integrative machine learning. Our analysis identified 31,140 cells from TNBC samples, categorized into nine cell types, with epithelial cells exhibiting the highest exosome-related scores. A total of 232 differentially expressed genes (DEGs) related to exosome-related scores were identified, with 19 prognostic genes selected through univariate Cox regression, leading to the construction of an EDPS. Low EDPS scores correlated with poorer clinical outcomes, higher immune infiltrates, and immune-related pathways. Furthermore, we identified notable differences in biological functions and mutation profiles between the two EDPS groups. Additionally, the low EDPS score group exhibited lower tumor immune dysfunction and exclusion (TIDE) scores, immunophenoscore (IPS), and higher immune checkpoint expression, suggesting better immunotherapy outcomes. In conclusion, while derived from exosome-related genes, the EDPS primarily reflects immune-active tumor microenvironments. This signature may help identify TNBC patients likely to benefit from immunotherapy, though further validation of its relationship to exosome biology is needed.

Abstract Image

TNBC中外泌体衍生特征的计算分析:整合单细胞和大量转录组学用于预后预测
三阴性乳腺癌(TNBC)是一种特别具有侵袭性的乳腺癌亚型,其靶向治疗选择有限。外泌体是细胞分泌的小膜泡,在细胞间通讯和物质交换中起着至关重要的作用。然而,外泌体相关基因(ERGs)在TNBC中的作用尚不清楚。在这里,我们分析了来自10个TNBC样本的单细胞RNA测序(scRNA-seq)和来自TCGA和METABRIC队列的大量RNA测序。从乳腺癌特异性ExoBCD数据库中筛选的121个EDPS开始,我们确定了外泌体活性细胞群,并通过综合机器学习获得了外泌体衍生预后特征(EDPS)。我们的分析从TNBC样本中鉴定出31,140个细胞,分为9种细胞类型,上皮细胞表现出最高的外泌体相关评分。共鉴定出232个与外泌体相关评分相关的差异表达基因(DEGs),通过单变量Cox回归选择了19个预后基因,从而构建了EDPS。低EDPS评分与较差的临床结果、较高的免疫浸润和免疫相关途径相关。此外,我们还发现了两个EDPS组在生物学功能和突变谱上的显著差异。此外,低EDPS评分组表现出较低的肿瘤免疫功能障碍和排斥(TIDE)评分、免疫表型评分(IPS)和较高的免疫检查点表达,表明免疫治疗效果较好。综上所述,虽然来源于外泌体相关基因,但EDPS主要反映了免疫活性肿瘤微环境。这一特征可能有助于识别可能受益于免疫治疗的TNBC患者,尽管需要进一步验证其与外泌体生物学的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cts-Clinical and Translational Science
Cts-Clinical and Translational Science 医学-医学:研究与实验
CiteScore
6.70
自引率
2.60%
发文量
234
审稿时长
6-12 weeks
期刊介绍: Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. CTS also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. Best-in-class methodologies and best practices are also welcomed as Tutorials. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. CTS welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信